Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anthem Inc.

www.antheminc.com

Latest From Anthem Inc.

Randomized Study Objectives Should Drive Choice Of Real-World Data Sources, Experts Say

Start with the trial’s primary objective and then figure out which RWD sources could help inform that outcome, experts say at Duke-Margolis meeting; however, design and underlying objectives of Novo Nordisk’s real-world use of trial of Ozempic have the FDA’s Robert Temple suggesting success will be a ‘longshot.’

Clinical Trials Research and Development Strategies

Federal Market Access: Implementing A Cross-Functional Strategy To Optimize Outcomes

Pharmaceutical companies can struggle to understand the business opportunities presented by the federal segment, in part due to perceptions of low profit margins and overwhelming regulatory hurdles that are required to do business in this market. As companies begin to reframe the value of the federal market, it is important to establish context from a global revenue perspective. 

BioPharmaceutical Market Intelligence

Migraine Market Gets Competitive With Second, Third CGRP Inhibitor Launches

CGRP inhibitors were a hot topic during third quarter earnings calls, with Amgen and Teva talking about reimbursement progress, while Lilly marked progress for its add-on treatment, Allergan calmed fears about Botox's migraine sales, and Alder said its intravenous drug is on track.

Launches Sales & Earnings

Amgen's Aimovig Riding High With Strong Prescriber, Payer Acceptance

New commercial head Murdo Gordon described Aimovig as one of the best launches he's ever seen and said growth should continue – though moderate – based on prescriber experience and rapid transitions from free drug to reimbursed prescriptions.

Sales & Earnings Pricing Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Services
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Anthem Inc.
  • WellPoint Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Anthem Inc.
  • Senior Management
  • Joseph R Swedish, Pres. & CEO
    Wayne S DeVeydt, EVP & CFO
    Craig Sammitt, MD, EVP & Chief Clin. Officer
  • Contact Info
  • Anthem Inc.
    Phone: (317) 488-6000
    120 Monument Cir.
    Indianapolis, IN 46204
    USA
UsernamePublicRestriction

Register